In-Vivo CAR T Update With Umoja Biopharma's David Fontana, Ph.D.
Business Of Biotech
00:00
The Challenges of CAR-T Therapy
We're really focused on solid tumors at Umoja. We have a universal car that has basically an anti-fitsi or anti-fluorocene car that we build. And tumor tags have one end of fluorocene, which binds to the car and activates it. So our play is used as a tracking for cars, right? So basically our universal car can find this folate tumor. Now folate tag all over the ovarian cancer bind to it, it caused the immune reaction and basically, kill the tumors. Our payloads are the cars that I mentioned, or it's our Rapamycin activated system too. The rest of our pipeline is really on how we deliver and sustain
Transcript
Play full episode
